The findings will allow for more targeted treatment approaches.
In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
The application deadline is Feb. 1.
OMRF VP of Clinical Affairs Judith James received a pair of distinguished honors at the American College of Rheumatology’s annual meeting.
The findings will help push clinicians closer to personalized medicine for lupus sufferers.
Scientists have long known lupus has a strong genetic component, but there also must be environmental triggers to activate the disease.